These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 28199996

  • 1. Importance of Timing First-Trimester Placental Growth Factor and Use of Serial First-Trimester Placental Growth Factor Measurements in Screening for Preeclampsia.
    Mosimann B, Amylidi-Mohr S, Höland K, Surbek D, Risch L, Raio L.
    Fetal Diagn Ther; 2017; 42(2):111-116. PubMed ID: 28199996
    [Abstract] [Full Text] [Related]

  • 2. Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia.
    Khalil A, Maiz N, Garcia-Mandujano R, Penco JM, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2016 Mar; 47(3):324-31. PubMed ID: 26387758
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Competing-risks model in screening for pre-eclampsia in twin pregnancy according to maternal factors and biomarkers at 11-13 weeks' gestation.
    Francisco C, Wright D, Benkő Z, Syngelaki A, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2017 Nov; 50(5):589-595. PubMed ID: 28556556
    [Abstract] [Full Text] [Related]

  • 7. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 30-34 weeks' gestation.
    Tsiakkas A, Saiid Y, Wright A, Wright D, Nicolaides KH.
    Am J Obstet Gynecol; 2016 Jul; 215(1):87.e1-87.e17. PubMed ID: 26875953
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Modified multiple marker aneuploidy screening as a primary screening test for preeclampsia.
    Huang T, Bedford HM, Rashid S, Rasasakaram E, Priston M, Mak-Tam E, Gibbons C, Meschino WS, Cuckle H, Mei-Dan E.
    BMC Pregnancy Childbirth; 2022 Mar 08; 22(1):190. PubMed ID: 35260099
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age.
    Erez O, Romero R, Espinoza J, Fu W, Todem D, Kusanovic JP, Gotsch F, Edwin S, Nien JK, Chaiworapongsa T, Mittal P, Mazaki-Tovi S, Than NG, Gomez R, Hassan SS.
    J Matern Fetal Neonatal Med; 2008 May 08; 21(5):279-87. PubMed ID: 18446652
    [Abstract] [Full Text] [Related]

  • 13. Placental growth factor and soluble fms-like tyrosine kinase-1 are useful markers for the prediction of preeclampsia but not for small for gestational age neonates: a longitudinal study.
    Rizos D, Eleftheriades M, Karampas G, Rizou M, Haliassos A, Hassiakos D, Vitoratos N.
    Eur J Obstet Gynecol Reprod Biol; 2013 Dec 08; 171(2):225-30. PubMed ID: 24035323
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. First-Trimester Placental Growth Factor for the Prediction of Preeclampsia in Nulliparous Women: The Great Obstetrical Syndromes Cohort Study.
    Boutin A, Demers S, Gasse C, Giguère Y, Tétu A, Laforest G, Bujold E.
    Fetal Diagn Ther; 2019 Dec 08; 45(2):69-75. PubMed ID: 30304731
    [Abstract] [Full Text] [Related]

  • 16. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study.
    Kim MY, Buyon JP, Guerra MM, Rana S, Zhang D, Laskin CA, Petri M, Lockshin MD, Sammaritano LR, Branch DW, Porter TF, Merrill JT, Stephenson MD, Gao Q, Karumanchi SA, Salmon JE.
    Am J Obstet Gynecol; 2016 Jan 08; 214(1):108.e1-108.e14. PubMed ID: 26432463
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Maternal serum placental growth factor isoforms 1 and 2 at 11-13, 20-24 and 30-34 weeks' gestation in late-onset pre-eclampsia and small for gestational age neonates.
    Nucci M, Poon LC, Demirdjian G, Darbouret B, Nicolaides KH.
    Fetal Diagn Ther; 2014 Jan 08; 35(4):249-57. PubMed ID: 24642536
    [Abstract] [Full Text] [Related]

  • 19. Repeated measures of placental growth factor, placental protein 13, and a disintegrin and metalloprotease 12 at first and second trimesters for preeclampsia screening.
    Boucoiran I, Suarthana E, Rey E, Delvin E, Fraser WB, Audibert F.
    Am J Perinatol; 2013 Sep 08; 30(8):681-8. PubMed ID: 23386402
    [Abstract] [Full Text] [Related]

  • 20. Angiogenic profile and smoking in the Finnish Genetics of Pre-Eclampsia Consortium (FINNPEC) cohort.
    Jääskeläinen T, Suomalainen-König S, Hämäläinen E, Pulkki K, Romppanen J, Heinonen S, Laivuori H, FINNPEC.
    Ann Med; 2017 Nov 08; 49(7):593-602. PubMed ID: 28537456
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.